Olodaterol for the treatment of chronic obstructive pulmonary disease
Purpose. Published data on the pharmacology, pharmacokinetics, efficacy, and safety of the once-daily, long-acting β2-agonist (LABA) olodaterol are reviewed. Summary. Olodaterol (Striverdi Respimat, Boehringer Ingelheim), a LABA with high selectivity for β2-adrenergic receptors, is indicated for the...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , |
| Format: | article |
| Published: |
2016
|
| Online Access: | http://hdl.handle.net/10725/4488 http://dx.doi.org/10.2146/ajhp150364 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://academic.oup.com/ajhp/article-abstract/73/15/1135/5101552 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|